Search

This article discusses the management of onchocerciasis, or river blindness, in Africa. The Onchocerciasis Control Programme in the Volta River Basin (OCP) was established in 1975 to combat the disease in seven West African countries. It later expanded to include four additional countries and changed its name to the Onchocerciasis Control Programme in West Africa (OCP). In 1995, the African Programme for Onchocerciasis Control (APOC) was launched to control the disease in all endemic countries in sub-Saharan Africa. APOC used community-directed treatment with ivermectin (CDTi) as its core strategy, leading to a significant decrease in infections and preventing millions of disability-adjusted life years (DALYs). The program also expanded its efforts to include other neglected tropical diseases (NTDs) susceptible to mass drug administration. APOC operates through a partnership between affected communities, governments, NGOs, and other stakeholders, with the World Health Organization (WHO) as the executing agency. APOC's success is attributed to its participative governance and engagement of communities through the CDTi strategy, empowering them to take responsibility for delivering treatment and expanding access to other health interventions. The document emphasizes the importance of community engagement, collaboration, and strengthening health systems at the community level in the planning, implementation, and monitoring of interventions for onchocerciasis control and other NTDs. The success [Extracted from the article]

Background: Onchocerciasis is endemic in 12 of the 14 health districts of Sierra Leone. Good treatment coverage of community-directed treatment with ivermectin was achieved between 2005 and 2009 after the 11-year civil conflict. Sentinel site surveys were conducted in 2010 to evaluate the impact of five annual rounds of ivermectin distribution. Methods: In total, 39 sentinel villages from hyper- and meso-endemic areas across the 12 endemic districts were surveyed using skin snips in 2010. Results were analyzed and compared with the baseline data from the same 39 villages. Results: The average microfilaridermia (MF) prevalence across 39 sentinel villages was 53.10% at baseline. The MF prevalence was higher in older age groups, with the lowest in the age group of 1–9 years (11.00%) and the highest in the age group of 40–49 years (82.31%). Overall mean MF density among the positives was 28.87 microfilariae (mf)/snip, increasing with age with the lowest in the age group of 1–9 years and the highest in the age group of 40–49 years. Males had higher MF prevalence and density than females. In 2010 after five rounds of mass drug administration, the overall MF prevalence decreased by 60.26% from 53.10% to 21.10%; the overall mean MF density among the positives decreased by 71.29% from 28.87 mf/snip to 8.29 mf/snip; and the overall mean MF density among all persons examined decreased by 88.58% from 15.33 mf/snip to 1.75 mf/snip. Ten of 12 endemic districts had > 50% reduction in MF prevalence. Eleven of 12 districts had ≥50% reduction in mean MF density among the positives. Conclusions: A significant reduction of onchocerciasis MF prevalence and mean density was recorded in all 12 districts of Sierra Leone after five annual MDAs with effective treatment coverage. The results suggested that the onchocerciasis elimination programme in Sierra Leone was on course to reach the objective of eliminating onchocerciasis in the country by the year 2025. Annual MDA with ivermectin should continue in all 12 districts and further evaluations are needed across the country to assist the NTDP with programme decision making. [ABSTRACT FROM AUTHOR]